TIDMHIK

Hikma Pharmaceuticals Plc

04 June 2018

London, 4 June 2018 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces the appointment of Henriette Nielsen to the newly created role of Chief Transformation Officer. In this role, Henriette will be responsible for leading a number of initiatives across Hikma's global operations to improve operational efficiency and ensure that Hikma achieves its strategic objectives. She will join Hikma's Executive Committee and will report directly to Siggi Olafsson, Hikma's Chief Executive Officer. Her appointment is effective from 4 June 2018.

Siggi Olafsson said, "Henriette brings extensive experience in pharmaceutical operations and transformation projects and has a strong track record of formulating and executing global strategic initiatives and developing multi-functional work plans. She brings an entrepreneurial attitude that I am confident will fit well within the Hikma culture."

Henriette joins Hikma from Teva Pharmaceuticals USA, where she was most recently Senior Vice President, Chief Transformation Officer, Global Marketing & Portfolio. Her previous experience includes founder of System Matters, a healthcare and impact investing consultancy, and General Counsel and EVP at Actavis Group. She also held senior roles at Alpharma, Netdoktor and Kromann Reumert.

-- ENDS --

Enquiries

Hikma Pharmaceuticals PLC

 
 Susan Ringdal 
  VP Corporate Strategy and Director    +44 (0)20 7399 2760/ +44 7776 
  of Investor Relations                  477050 
 Virginia Spring                        +44 (0)20 3892 4389/ +44 7973 
  Investor Relations Manager             679502

FTI Consulting

 
 Ben Atwell/Brett Pollard    +44 (0)20 3727 1000

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRASSWFDFFASEIM

(END) Dow Jones Newswires

June 04, 2018 04:00 ET (08:00 GMT)

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Hikma Pharmaceuticals Charts.
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Hikma Pharmaceuticals Charts.